Multiple isoforms of the tumor suppressor myopodin are simultaneously transcribed in cancer cells

Area of Science:

• Molecular Biology
• Cancer Research
• Genetics

Background:

• Myopodin, an actin-associated protein, is crucial for muscle function and often lost in invasive prostate cancers.
• Existing public databases proposed two human myopodin isoforms, differing significantly from known mouse and human variants.

Purpose of the Study:

• To investigate the expression and diversity of human myopodin isoforms.
• To identify and characterize novel myopodin transcripts and their protein products.

Main Methods:

• Rapid amplification of cDNA ends (RACE) to identify new transcripts.
• Reverse transcription polymerase chain reaction (RT-PCR) to analyze isoform transcription.
• Expression studies in mammalian cell lines to confirm protein translation.

Main Results:

• A novel myopodin transcript (Myo2) was identified, alongside two previously predicted isoforms (Myo1 and Myo3).
• All three human myopodin isoforms (Myo1-3) are transcribed in various mammalian cell lines.
• These isoforms translate into full-length proteins of distinct sizes (1093, 1109, and 1261 amino acids) with a common N-terminal PDZ domain and variable C-terminal regions.

Conclusions:

• Mammalian cells express at least three distinct myopodin isoforms.
• These findings necessitate a re-evaluation of myopodin's role as a tumor suppressor gene.
• Further research is required to understand the functional implications of these different myopodin isoforms in both human and mouse systems.